Patent classifications
A01N63/00
Granule Formulations as Biochemical Agricultural Products
The present disclosure includes the composition and methods of a granule formulation consist using a liquid biological active that has great handling properties yet still efficacious. The biological active is absorbed into or spray onto a mixture of carriers, dispersants, and/or wetting agents. When the product is formulated as a granule, it has good durability and does not dust which increases handleability of the product during application.
Granule Formulations as Biochemical Agricultural Products
The present disclosure includes the composition and methods of a granule formulation consist using a liquid biological active that has great handling properties yet still efficacious. The biological active is absorbed into or spray onto a mixture of carriers, dispersants, and/or wetting agents. When the product is formulated as a granule, it has good durability and does not dust which increases handleability of the product during application.
Biological control of crown gall disease on grapevines
Derivatives of Agrobacterium vitis strain F2/5 are disclosed. These derivatives were generated following homologous recombination with an internal fragment of targeted genes resulting in gene disruption by insertion of a copy of suicide vector pVIK165. The genes disrupted were F-avi5813 encoding a phosphopantetheinyltransferase, F-avi4329 encoding an aminotransferase and F-avi0838 (rirA) encoding an iron responsive transcriptional regulator. Such derivatives control crown gall on grapevines. In addition, these derivatives did not induce roots necrosis but enhanced root development and callus formation. On young stem explants, it was shown as well that the F2/5 derivatives are necrosis-negative.
Bifidobacterium longum
The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.
Treatment of immunosuppression-related disorders
Disclosed are methods of using blastomere-like stem cells to decrease a level of myeloid-derived suppressor cells (MDSCs). A method for decreasing a level of myeloid-derived suppressor cells (MDSCs) in a human subject, including: injectionally, orally or transdermally administering to the human subject an amount of human blastomere-like stem cells, autologous to the human subject, at 1×10.sup.8 to 1×10.sup.11 cells each time once every two weeks, for example.
Bio-stimulant for improved plant growth and development
A bio-stimulant composition for obtaining improved plant growth, either combined or uncombined with urea and/or other agricultural compounds, as well of methods of producing and using said composition.
Compositions for stabilizing bacillus spores and methods of use thereof
The invention provides methods for providing Bacillus spores for application to agricultural soil or plant material. The methods comprise suspending the Bacillus spores in a liquid consisting essentially of water and an organic acid, including acetic acid, wherein the acid lowers the pH so that the spores are inhibited from germination and growth; and so that growth of unwanted microorganisms in the suspension is prevented. Compositions formed according to the methods of the invention are also provided.
Decellularized adipose cell growth scaffold
Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold.
Compositions and methods for deploying a transgenic refuge as a seed blend
Methods and compositions for deploying refuge seeds together with transgenic crop seeds are provided. The refuge seeds can be non-transgenic seeds of a similar variety to that of the transgenic crop seeds, or the refuge seeds can be a transgenic variety.
Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof
The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.